CAR T-Cell Therapy Puts Severe Rheumatoid Arthritis Into Remission in First Clinical Trial
Researchers at Charité report promising results from the first CAR T-cell trial for treatment-refractory rheumatoid arthritis, with all six patients improving and three achieving sustained medication-free remission. The post CAR T-Cell Therapy Puts Severe Rheumatoid Arthritis Into Remission in First Clinical Trial appeared first on GEN - Genetic Engineering and Biotechnology News .
CAR T-cell therapy has shown promising results in treating severe rheumatoid arthritis (RA) in an initial clinical trial. Six patients with particularly severe forms of the chronic autoimmune disorder were enrolled in the study at Charité—Universitätsmedizin Berlin. The treatment involved administering a single infusion of autologous fully human CD19 CAR T cells called miv-cel.
All six patients had previously received up to eight targeted or biologic therapies, with no significant improvement in their condition. The therapy resulted in substantial disease activity decrease in all participants, and three of the patients achieved sustained remission without requiring any medication for their RA within a year of treatment.
The trial demonstrated that CAR T-cell therapy could potentially target and reset the pathological B-cell memory, providing a fresh start for the B-cell system. Although responses varied among patients, and some cases saw disease recurrence, the safety profile of the treatment was considered encouraging. Researchers aim to compare the new treatment with an approved drug targeting B cells in a subsequent phase of the trial to assess its effectiveness and long-term impact.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
